|
A friend of mine, Shahram Mori, recently pointed to this issue -- as a way to play trickle down from recent sector liquidity. Current market cap is $43 million.
Tuesday February 15, 9:22 am Eastern Time
Company Press Release
SOURCE: DGI BioTechnologies, LLC.
DGI BioTechnologies, LLC., Makes Key Additions to
Scientific Team
EDISON, N.J., Feb. 15 /PRNewswire/ -- DGI BioTechnologies, LLC. (DGI), which is majority owned by New Brunswick
Scientific Co., Inc. (Nasdaq: NBSC - news), today announced that it has made the following key additions to its core scientific
team:
Director of Protein Technologies-Michael Lennick, Ph.D.
Director of Molecular Biology-Neil I. Goldstein, Ph.D.
Group Leader of High-Throughput Screening (HTS)-Paul W. Fletcher, Ph.D.
Dr. Lennick, 47, is a protein biochemist with over 20 years' experience in research and development, specializing in monoclonal
antibodies, vaccines, recombinant proteins and human blood products, complemented by a background in immunochemistry
and assay development. Most recently, he was Assistant Director in Charge of Pharmaceutical Processing for Medarex
Corporation in Clinton, New Jersey. Dr. Lennick earned his Ph.D. in Biology from Wesleyan University in 1982 and was a
postdoctoral fellow with the American Red Cross in Bethesda, Maryland, from 1982 to 1984.
Dr. Goldstein, 51, well versed in all aspects of immunology, molecular biology, biochemistry, and cell biology, joined DGI from
GenQuest, Inc., New York, New York, where he was Vice President and Director of Molecular and Cell Biology. Dr.
Goldstein received his Ph.D. in Microbiology from Rutgers University in 1975 and was a postdoctoral fellow, The Waksman
Institute of Microbiology at Rutgers University (1975-76); and The Wistar Institute (1976- 78).
Dr. Fletcher, 48, is a biochemical pharmacologist with over 20 years of experience in research and development, specializing in
receptor biochemistry, signal transduction and assay development. Before joining DGI, he served as Manager of Pharmacology
and as a Program Manager in Wound Healing for ProCyte Corporation in Redmond, Washington. Dr. Fletcher attended the
University of Wyoming (1975-78) where he received his Ph.D. in Biochemistry and Reproductive Physiology, and was an NIH
postdoctoral fellow, Biochemical Endocrinology, (1978-80) at Colorado State University.
DGI President and Chief Executive Officer Dr. Arthur J. Blume said: ''With DGI poised to become an integral part of future
drug discoveries, one of our many objectives is the establishment of a comprehensive infrastructure to support strategic
growth.''
He continued, ''Dr. Lennick's expertise gives DGI the ability to obtain sufficient, often difficult-to-make quantities of drug
targets needed for HTS. Dr. Goldstein brings master skills with nucleic acids required for the generation and use of our
surrogate libraries. These libraries are utilized in target validation and selection and providing the surrogates needed for DGI's
site directed assays (SDAs). Dr. Fletcher's extensive background in molecular pharmacology provides DGI the guidance
required to build, validate and run its SDAs on today's leading-edge HTS equipment, and to oversee the database management
vital to identifying good drug-discovery leads.
''The additions of Drs. Lennick, Goldstein and Fletcher, by virtue of their unique knowledge and extensive experience, further
broaden our capabilities and strengthen our organization as we continue to evolve,'' he concluded.
DGI BioTechnologies, LLC., majority owned by New Brunswick Scientific Co., Inc., has developed a proprietary process
that offers pharmaceutical and biotechnology companies an improved method of identifying novel, small molecule, orally
available drug leads.
This press release includes statements that may constitute forward-looking statements made pursuant to the Safe Harbor
provision of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties, including
without limitation, risks relating to the development by DGI of its technology, that could cause actual results to differ materially
from the forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking
statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual
results to differ materially from those projected.
SOURCE: DGI BioTechnologies, LLC. |
|
